FindTrial
Sign In

Study on Pre-treatment Prediction of HER2 Full Expression Lineage of Breast Cancer Based on Deep Learning System of DCE-MRI Radiomics

Study on Pre-treatment Prediction of HER2 Full Expression Lineage of Breast Cancer Based on Deep Learning System of DCE-MRI Radiomics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116354
Enrollment
Unknown
Registered
2026-01-08
Start date
2026-01-10
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Gold Standard:Core Needle Biopsy
Index test:age, menopausal status, clinical TNM staging, histological grade, ER, PR, Ki-67

Sponsors

The affiliated hospital of southwest medical university
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1.woman; 2.invasive breast cancer; 3.complete information;

Exclusion criteria

Exclusion criteria: 1.man; 2.DCIS; 3.incomplete information;

Design outcomes

Primary

MeasureTime frame
Her2: positive, low expression, ultra-low expression, negative;—

Countries

China

Contacts

Public ContactPan Guangrui

The affiliated hospital of southwest medical university

leftarrow@163.com+86 830 8950792

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026